TEVA-CLONIDINE TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CLONIDINE HYDROCHLORIDE

Prieinama:

TEVA CANADA LIMITED

ATC kodas:

C02AC01

INN (Tarptautinis Pavadinimas):

CLONIDINE

Dozė:

0.2MG

Vaisto forma:

TABLET

Sudėtis:

CLONIDINE HYDROCHLORIDE 0.2MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100/500

Recepto tipas:

Prescription

Gydymo sritis:

CENTRAL ALPHA-AGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0108891002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2013-12-13

Prekės savybės

1
PRODUCT MONOGRAPH
PR
TEVA-CLONIDINE
(Clonidine Hydrochloride)
0.1 mg and 0.2 mg Tablets
USP
Antihypertensive
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 171843
Date of Revision:
April 25, 2014
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
11
OVERDOSAGE
........................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
13
STORAGE
AND
STABILITY
.................................................................................................
14
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 14
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL
INFORMATION
.................................................................................
16
DETAILED
PHARMACOLOGY
............................................................................................
17
TOXICOLOGY
...........................